ELC Group

ELC Group in early-stage development of novel influenza vaccine

Cambridge, UK, 16th June 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it has signed up for the early-stage development of a novel vaccine targeting prevention of influenza. The project signals ELC Group’s entry into the pharmaceutical development market.

The vaccine development will be overseen by a specialist R&D team at ELC Group, including regulatory vaccines experts who have worked on and regulated a number of key worldwide paediatric vaccines. The highly experience team includes a number of current advisers to the World Health Organisation.

ELC Group expands into pharmaceutical product development market

Cambridge, UK, 9th June 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it is expanding into the pharmaceutical development market with the creation of an extensive product portfolio targeting a range of therapeutic areas.

The products, currently under development by an ELC Group specialist team at R&D laboratories will be marketed across the US, EU, LATAM, MENA and China. ELC Group estimates that the complete portfolio will generate an estimated value of 2 Billion USD in annual sales after initial launch. ELC Group intends to sign key strategic global partners for licensing and distribution.

The new product portfolio will address a range of therapeutic areas, including oncology, cardiovascular treatment, diabetes and pain management and ophthalmic solutions. The product set is being developed using the very latest techniques, including advanced technologies such as liposome systems and soft gel.

ELC Group signs 1.5 million Euro regulatory affairs contract with Chinese pharma giant

Cambridge, UK, 21st April 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it has been awarded a 1.5 million Euro contract by one of China’s biggest pharmaceutical companies.

The contract award is a major endorsement of ELC Group’s new Concept to Commercialisation solution approach, which delivers a highly integrated portfolio of regulatory affairs consultancy services to customers, from the development stage through to the implementation of clinical trials, completion of product registration, and successful marketing of the product.

The major project, which will see two products taken through ELC Group’s end-to-end Concept to Commercialisation service, is expected to be complete by the end of 2016. The customer, one of the top 25 Chinese pharmaceutical companies, is an active pharmaceutical ingredient company that is moving towards the finished formulation business.

Fast-growing regulatory affairs service provider ELC Group expands corporate presence in Czech Republic

Cambridge, UK, 24th February 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it is expanding its office presence in Prague in the Czech Republic due to accelerating company growth. From May, ELC Group will be occupying nearly 2000 square metres of offices at Danube House, located in the prime River City Prague business district.

The move is being fuelled by ELC Group’s rapidly expanding customer base, which includes recent major contract wins in China and the US. The increased office space will accommodate ELC Group’s growing team of project management staff and subject matter experts, with staff numbers based in the Czech capital set to almost double within the next three months.

ELC GROUP to present at “Regulatory & Legal Affairs in Russia 2015” Conference

Cambridge, UK, 2nd February 2015 – ELC Group, one of the fastest-growing providers of regulatory affairs, today announces that its Senior Regulatory Affairs Manager Dr Parvinder Punia will be an invited speaker at the 3rd Annual Regulatory & Legal Affairs in Russia conference being held at the Marriott Grand Hotel in Moscow from February 10th – 12th 2015.

ELC Group Appoints Dr. Siddharth Chachad as Head of Global Clinical Development and Medical Affairs

Cambridge, UK, 20 August, 2014: ELC Group, one of the fastest-growing providers of regulatory affairs, today announces the appointment of internationally acclaimed clinical pharmacologist Dr. Siddharth Chachad as Head of Global Clinical Development and Medical Affairs. A member of the UK Faculty of Pharmaceutical Medicine, Dr. Chachad is an expert in the design and execution of pre-clinical and clinical development programme for drug products across dosage forms and therapeutic categories. Dr. Chachad has gained considerable career experience in the delivery medical services, medico-regulatory affairs and clinical development, and has worked across global clinical development strategy and operations of generics, new drugs and biosimilars. Dr. Siddharth’s extensive expertise covers all phases of clinical studies, including pre-clinical, pharmacodynamic studies, bioequivalence, PK in patients and full-blown clinical efficacy and safety studies.

Forums:

Speciality:

Pages

Subscribe to RSS - ELC Group